menu

Heart Failure Grand Rounds: 3 Things You Need to Know About Cardiac Contractility Modulation

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Heart Failure Grand Rounds: 3 Things You Need to Know About Cardiac Contractility Modulation

15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Cardiac contractility modulation (CCM) is a novel, approved, implantable therapy that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Javed Butler, MD, MBA, MPH
    President, Baylor Scott and White Research Institute
    Dallas, TX
    Distinguished Professor of Medicine, University of Mississippi Medical Center
    Jackson, MS 

    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Faculty:
    William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
    Professor of Medicine, Physiology, and Cell Biology
    College of Medicine Distinguished Professor
    Division of Cardiovascular Medicine
    The Ohio State University
    Columbus, OH 

    Consulting Fees: Boehringer Ingelheim, Cardionomic, Impulse Dynamic, Respicardia, Inc., Tegosens, Inc., Vectorious

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy (GDMT)
    • Review the latest clinical data on the use of cardiac contractility modulation (CCM) therapy in patients with heart failure
    • Select patients with heart failure who would benefit from CCM therapy and refer them directly to an EP
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Impulse Dynamics, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Cardiac contractility modulation (CCM) is a novel, approved, implantable therapy that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Javed Butler, MD, MBA, MPH
    President, Baylor Scott and White Research Institute
    Dallas, TX
    Distinguished Professor of Medicine, University of Mississippi Medical Center
    Jackson, MS 

    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Faculty:
    William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
    Professor of Medicine, Physiology, and Cell Biology
    College of Medicine Distinguished Professor
    Division of Cardiovascular Medicine
    The Ohio State University
    Columbus, OH 

    Consulting Fees: Boehringer Ingelheim, Cardionomic, Impulse Dynamic, Respicardia, Inc., Tegosens, Inc., Vectorious

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy (GDMT)
    • Review the latest clinical data on the use of cardiac contractility modulation (CCM) therapy in patients with heart failure
    • Select patients with heart failure who would benefit from CCM therapy and refer them directly to an EP
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Impulse Dynamics, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Schedule29 Mar 2024